N-L-cysteinyl-L-valyl-L-isoleucyl-L-leucine | 133824-32-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-L-cysteinyl-L-valyl-L-isoleucyl-L-leucine
• 英文别名: CVIL；(S)-2-{(S)-2-[(S)-2-((R)-2-Amino-3-mercapto-propionylamino)-3-methyl-butyrylamino]-3-methyl-pentanoylamino}-4-methyl-pentanoic acid；(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
• CAS: 133824-32-5
• 化学式: C₂₀H₃₈N₄O₅S
• 分子量: 446.612
• InChiKey: ULSBWQWKNJASCN-QXKUPLGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  30
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  152
• 氢给体数：
  6
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  H-Cys(Trt)-Val-Ile-Leu-OtBu 在 三乙基硅烷 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 N-L-cysteinyl-L-valyl-L-isoleucyl-L-leucine
  参考文献：
  名称：

  用于蛋白质表面识别的模块组装：geranylgeranyltransferase I二价抑制剂，可同时靶向内部和外部蛋白质表面。

  摘要：

  设计用于同时靶向蛋白质表面多个位点的合成化学探针由于其作为蛋白质-蛋白质相互作用的位点特异性调节剂的潜在应用而受到关注。报道了一种基于模块组装同时识别内部和外部蛋白质表面的针对哺乳动物I型香叶基香叶基转移酶（GGTase I）的二价抑制剂的新方法。在这项研究中合成的抑制剂由通过烷基间隔基连接的两个模块组成。一个是四肽CVIL模块，用于与内部蛋白质表面（活性口袋）结合，另一个是3,4,5-烷氧基取代的苯甲酰基基序，其中包含三个氨基烷基，旨在与活性区域附近的带负电荷的蛋白质外表面结合地点。通过基于荧光光谱法的两种不同的酶抑制试验以及将[（3H）]标记的异戊二烯基结合到蛋白质底物上来筛选化合物。二价抑制剂以亚微摩尔范围的K（i）值阻断GGTase I的酶促活性，分别比四肽CVIL和苯甲酸甲酯衍生物高一个数量级，并且效力高出150倍以上。二价化合物6和8被证明是竞争性抑制剂，表明CVIL模块将整个分子锚定在GGTase

  DOI：

  10.1002/chem.200701634

文献信息

• INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS
  申请人：TABACZYNSKI David A.

  公开号：US20160303146A1

  公开（公告）日：2016-10-20

  This invention provides methods and pharmaceutical compositions that can treat neuroinflammatory disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms. The methods involve administering to a patient an inhibitor of the mevalonate-dependent pathway, an inhibitor of the non-mevalonate pathway, or combination of such inhibitors.
• INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS
  申请人：TABACZYNSKI David A.

  公开号：US20160375041A1

  公开（公告）日：2016-12-29

  The invention provides methods and pharmaceutical compositions that can treat autoimmune disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms. The methods involve administering to a patient an inhibitor of the mevalonate-dependent pathway, an inhibitor of the non-mevalonate pathway, or combination of such inhibitors.
• [EN] INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS<br/>[FR] INHIBITION DE VOIES DE BIOSYNTHÈSE D'ISOPRÉNOÏDES POUR TRAITER DES TROUBLES AUTO-IMMUNS
  申请人：TABACZYNSKI DAVID A

  公开号：WO2015084721A1

  公开（公告）日：2015-06-11

  The invention provides methods and pharmaceutical compositions that can treat autoimmune disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms. The methods involve administering to a patient an inhibitor of the mevalonate-dependent pathway, an inhibitor of the non-mevalonate pathway, or combination of such inhibitors.
• [EN] INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS<br/>[FR] INHIBITION DE VOIES DE BIOSYNTHÈSE D'ISOPRÉNOÏDES POUR TRAITER DES TROUBLES NEURO-INFLAMMATOIRES
  申请人：TABACZYNSKI DAVID A

  公开号：WO2015089349A1

  公开（公告）日：2015-06-18

  This invention provides methods and pharmaceutical compositions that can treat neuroinflammatory disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms. The methods involve administering to a patient an inhibitor of the mevalonate-dependent pathway, an inhibitor of the non-mevalonate pathway, or combination of such inhibitors.
• Module Assembly for Protein-Surface Recognition: Geranylgeranyltransferase I Bivalent Inhibitors for Simultaneous Targeting of Interior and Exterior Protein Surfaces
  作者：Shinnosuke Machida、Kakeru Usuba、Michelle A. Blaskovich、Akiko Yano、Kazuo Harada、Saïd M. Sebti、Nobuo Kato、Junko Ohkanda

  DOI：10.1002/chem.200701634

  日期：2008.2.8

  probes designed to simultaneously targeting multiple sites of protein surfaces are of interest owing to their potential application as site specific modulators of protein-protein interactions. A new approach toward bivalent inhibitors of mammalian type I geranylgeranyltransferase (GGTase I) based on module assembly for simultaneous recognition of both interior and exterior protein surfaces is reported. The

  设计用于同时靶向蛋白质表面多个位点的合成化学探针由于其作为蛋白质-蛋白质相互作用的位点特异性调节剂的潜在应用而受到关注。报道了一种基于模块组装同时识别内部和外部蛋白质表面的针对哺乳动物I型香叶基香叶基转移酶（GGTase I）的二价抑制剂的新方法。在这项研究中合成的抑制剂由通过烷基间隔基连接的两个模块组成。一个是四肽CVIL模块，用于与内部蛋白质表面（活性口袋）结合，另一个是3,4,5-烷氧基取代的苯甲酰基基序，其中包含三个氨基烷基，旨在与活性区域附近的带负电荷的蛋白质外表面结合地点。通过基于荧光光谱法的两种不同的酶抑制试验以及将[（3H）]标记的异戊二烯基结合到蛋白质底物上来筛选化合物。二价抑制剂以亚微摩尔范围的K（i）值阻断GGTase I的酶促活性，分别比四肽CVIL和苯甲酸甲酯衍生物高一个数量级，并且效力高出150倍以上。二价化合物6和8被证明是竞争性抑制剂，表明CVIL模块将整个分子锚定在GGTase